Jordan Sloshower

Jordan Sloshower is a research fellow in addiction psychiatry at Yale University. His research and clinical interests focus on therapeutic applications of psychedelic substances and he is currently an investigator and therapist in two clinical trials of psilocybin-assisted therapy in the treatment of major depressive disorder (MDD).

CV

Jordan Sloshower is a board-certified psychiatrist specializing in integrative approaches to mental health. Having completed his medical and psychiatric training at Yale University, Dr. Sloshower possesses a solid foundation in conventional psychiatric and psychotherapeutic approaches. His work is complemented by a unique perspective and skillset resulting from prior training in anthropology and global health, and deep interests in ethnobotany and alternative approaches to wellness, such as yoga and meditation.

Dr. Sloshower has received training in psychedelic therapy from Jeffrey Guss at New York University and Bill Richards at Johns Hopkins, and is completing training with MAPS in MDMA-assisted psychotherapy. He is co-founder of the Yale Psychedelic Science Group and has presented at several conferences on psychedelic medicine.

Notable Research Papers

• Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame (Sloshower, et al., 2020)
• Neuroendocrine associations underlying the persistent therapeutic effects of classic serotonergic psychedelics (Sloshower, et al., 2018)
• Integrating psychedelic medicines and psychiatry: theory and methods of a model clinic (Sloshower, 2018)

Find more on ResearchGate, Google Scholar or PubMed

In our database you will also find him as an author on many more papers.

Media

He has given public talks:

• Integrating Plant Medicines & Psychiatry: Theory and Methods of a Model Clinic (Psychedelic Science Summit, 2017)
• Plant medicines and psychiatry: “Critical paradigm integration (AYA2016 | ICEERS, 2016)

More media:

• Psychedelic drugs can help treat PTSD caused by racism, discrimination: researchers (CTV News, 2020)
• A Handful of Start-Ups Is Developing Psychedelic Drugs for Mental Illnesses. It Could Be a Bad Trip for Investors. (Barron’s Magazine, 2020)